Ronald Scott

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD.

3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors.

Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans.

MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA.

Part of Novartis AG, Chiron Behring & Co. is a German company that supplies and develops new vaccine products for adults and children. The company is based in Marburg, Germany. Chiron Behring was acquired by Chiron Corp. from Hoechst AG on April 01, 1998 for $111.90 million.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom.

EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy.

H3 AEROSPACE GmbH & Co. KG engages in the acquisition, manufacture, marketing, leasing and sale of airplanes. The company was founded by Antoinette Hiebeler-Hasner in 2006 and is headquartered in Tussenhausen-Mattsies, Germany.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

The European Research Council is an organization that provides grants for research projects. The organization is based in Brussels, Belgium. As a grantee, individuals are required to submit scientific and financial reports for assessment by ERC Scientific Officers. The organization emphasizes the importance of research ethics and compliance with legislation, disciplinary norms, and protection of research subjects. The responsibility for ethics lies with the individuals conducting the research, while the formal accountability lies with the signatory of the Grant Agreement, the Host Institution.

MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million.

Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.